Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna’s entire drug pipeline is generated from its proprietary RNA interference (RNAi) technology platform, which is believed to improve upon existing RNAi technologies. RNAi is a highly potent and specific mechanism for silencing the activity of a targeted disease-driving gene. Dicerna’s discovery approach is based on proprietary double-stranded RNA molecules which the Company believes maximizes RNAi potency.
TypePublic
HQCambridge, US
Founded2007
Size (employees)47 (est)
Websitedicerna.com
Dicerna Pharmaceuticals was founded in 2007 and is headquartered in Cambridge, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Dicerna Pharmaceuticals

Douglas M. Fambrough

Douglas M. Fambrough

President and Chief Executive Officer
Bob D. Brown

Bob D. Brown

Chief Scientific Officer, Senior Vice President
Jack Green

Jack Green

CFO
Jennifer Lockridge

Jennifer Lockridge

Senior Vice President, Program Development
David Miller

David Miller

Senior Vice President, Corporate Operations
Ralf Rosskamp

Ralf Rosskamp

Chief Medical Officer
Show more

Dicerna Pharmaceuticals Office Locations

Dicerna Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
87 Cambridge Park Dr
Show all (1)
Report incorrect company information

Dicerna Pharmaceuticals Financials and Metrics

Dicerna Pharmaceuticals Revenue

Dicerna Pharmaceuticals's revenue was reported to be $1.18 m in FY, 2017
USD

Net income (Q2, 2018)

(51.2m)

EBIT (Q2, 2018)

(51.7m)

Market capitalization (15-Oct-2018)

814.0m

Closing stock price (15-Oct-2018)

13.2

Cash (30-Jun-2018)

42.4m
Dicerna Pharmaceuticals's current market capitalization is $814 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

184.0k295.0k1.2m

Revenue growth, %

60%

General and administrative expense

15.6m19.2m18.3m25.9m

R&D expense

29.5m44.0m41.7m37.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018

Revenue

184.0k184.0k184.0k162.0k133.0k252.0k474.0k

General and administrative expense

2.8m4.4m3.7m5.4m4.5m4.9m4.5m4.7m4.3m5.5m6.3m6.7m9.1m

R&D expense

5.3m6.8m7.5m8.7m11.9m12.1m11.3m11.0m10.1m8.9m9.3m9.0m20.2m

Operating expense total

8.1m11.2m11.2m14.1m16.4m17.0m15.7m15.7m14.4m14.4m15.6m15.7m54.8m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.1m56.1m20.9m68.8m

Accounts Receivable

254.7m805.4k

Inventories

1.2m1.5m2.0m

Current Assets

97.3m96.1m47.8m118.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018

Cash

133.8m77.7m31.8m22.6m25.9m52.9m27.6m29.2m32.5m22.9m38.8m31.0m42.4m

Current Assets

134.7m101.3m93.7m89.1m96.7m95.7m81.8m70.7m59.4m36.2m91.7m79.8m87.6m

PP&E

911.0k1.5m1.9m2.3m2.6m2.7m2.5m2.5m2.4m2.0m1.8m1.7m

Total Assets

135.9m124.2m116.0m92.7m127.7m113.6m85.5m74.3m62.9m39.4m94.7m82.7m89.7m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(47.9m)(62.8m)(59.5m)(60.0m)

Depreciation and Amortization

848.0k727.0k840.0k778.0k

Inventories

(44.3m)

Accounts Payable

(97.0k)1.4m1.6m626.0k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2018

Net Income

(10.8m)(11.4m)(11.2m)(14.1m)(16.2m)(16.9m)(15.7m)(15.6m)(14.2m)(14.2m)(51.2m)

Depreciation and Amortization

164.0k393.0k

Accounts Payable

1.1m1.2m525.0k1.6m1.4m2.4m3.2m3.7m4.1m(1.2m)

Cash From Operating Activities

(10.6m)(32.3m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Dicerna Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Dicerna Pharmaceuticals News and Updates

Report incorrect company information

Dicerna Pharmaceuticals Blogs

Dicerna Announces Late-Breaking Data from the PHYOX Phase 1 Clinical Trial of DCR-PHXC Will Be Presented at ASN Kidney Week 2018

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 5, 2018-- Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that late-breaking data from the PHYOX Phase 1 trial of DCR-PHXC for the treatment of primary

Dicerna to Participate in Two Upcoming Investor Conferences

Dicerna to Participate in Two Upcoming Investor Conferences Content Import Mon, 09/24/2018 - 07:31 Dicerna to Participate in Two Upcoming Investor Conferences Sep 24, 2018 This release is a backfill from a News Wire General CAMBRIDGE,…

Dicerna Pharmaceuticals Company Life and Culture

Report incorrect company information